DeepMed Research

Cancer Hospital, Chinese Academy of Medical Sciences

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

SBRT With DIBH for HCC After TACE and Lipiodol Marking

Not Applicable

Active, not recruiting

Conditions: Hepatocellular Carcinoma

Interventions: Procedure: Lipiodol marking

First Posted Date: 2021-08-25

Last Posted Date: 2024-01-10

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 30

Registration Number: NCT05021250

Locations: 🇨🇳
Bo Chen, Beijing, Beijing, China

Multi-Centre, Observational Study on Safety of Bevacizumab Biosimilars in Clinical Practice Among Chinese Patients

Conditions: Biosimilar

Interventions: Drug: Bevacizumab

First Posted Date: 2021-08-17

Last Posted Date: 2021-08-17

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 272

Registration Number: NCT05009017

Locations: 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳
Wenzhou Zhang, Zhengzhou, Henan, China

A Proof of Concept Study of Pan-cancer Early Detection by Liquid Biopsy

Completed

Conditions: Cancer

Interventions: Device: Multi-cancer early detection test

First Posted Date: 2021-07-22

Last Posted Date: 2024-12-27

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 2305

Registration Number: NCT04972201

Locations: 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China

Camrelizumab Combined With Pemetrexed and Carboplatin for the Study of EGFR-mutated Lung Squamous NSCLC Treatment

Not Applicable

Conditions: Lung Cancer Stage II

Interventions: Drug: Camrelizumab+ pemetrexed + platinum

First Posted Date: 2021-07-21

Last Posted Date: 2021-07-21

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 58

Registration Number: NCT04970043

MRI-guided Lateral Lymph Node Dissection in Rectal Cancer

Recruiting

Conditions: Rectal Cancer

Interventions: Procedure: TME+Lateral lymph node dissection.

First Posted Date: 2021-04-20

Last Posted Date: 2021-04-26

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 268

Registration Number: NCT04850027

Locations: 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, Beijing, China

A Neoadjuvant Hepatocellular Carcinoma Study of Camrelizumab in Combination With Apatinib and Oxaliplatin

Phase 2

Not yet recruiting

Conditions: Hepatocellular Carcinoma Resectable

Interventions: Drug: Apatinib Mesylate
Drug: Camrelizumab
Drug: Oxaliplatin

First Posted Date: 2021-04-20

Last Posted Date: 2021-04-20

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 15

Registration Number: NCT04850040

Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer

Phase 3

Recruiting

Conditions: Chemotherapy Effect
Esophagus Cancer
Esophagogastric Junction Cancer
Chemoradiation
Targeted Therapy
Immunotherapy

Interventions: Radiation: Radiotherapy
Drug: Platinum based chemotherapy
Drug: Paclitaxel based chemotherapy
Drug: 5-FU Analog based chemotherapy
Drug: Immunotherapy
Drug: Nimotuzumab

First Posted Date: 2021-03-30

Last Posted Date: 2024-12-13

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 2000

Registration Number: NCT04821778

Locations: 🇨🇳
Department 4th of Radiation Oncology, Anyang Cancer Hospital, Anyang, Henan, China
🇨🇳
Department of Radiation oncology, Jiangsu Province Hospital/The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China
🇨🇳
Hunan Cancer Hospital, the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China

and more 2 locations

Neoadjuvant Treatment Modalities in Esophageal Cancer

Phase 3

Recruiting

Conditions: Esophagogastric Juction Cancer
Surgery
Immunotherapy
Esophageal Cancer
Chemotherapy Effect
Targeted Therapy
Chemoradiation

Interventions: Drug: Platinum based chemotherapy
Drug: Paclitaxel based chemotherapy
Radiation: Radiotherpay
Procedure: Surgery
Drug: Immunotherapy
Drug: 5-FU Analog based chemotherpay
Drug: Nimotuzumab

First Posted Date: 2021-03-30

Last Posted Date: 2023-11-24

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 2000

Registration Number: NCT04821843

Locations: 🇨🇳
Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, China

Pan-canceR Early-Stage deteCtion by lIquid Biopsy tEchNique projecT

Conditions: Cancer

Interventions: Device: Multi-cancer early detection test

First Posted Date: 2021-03-30

Last Posted Date: 2021-06-02

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 11879

Registration Number: NCT04822792

Locations: 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China

Phase II Study of Concurrent Lenvatinib and Radiotherapy for Advanced HCC

Phase 2

Active, not recruiting

Conditions: Radiotherapy
Lenvatinib
Hepatocellular Carcinoma

Interventions: Radiation: concurrent lenvatinib and Radiotherapy, followed lenvatinib maintenance

First Posted Date: 2021-03-10

Last Posted Date: 2024-01-10

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 64

Registration Number: NCT04791176

Locations: 🇨🇳
Bo Chen, Beijing, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy